SCHEMBL845658

SCHEMBL845658

C#C[CH][CH2]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL125961 0.67
SCHEMBL7570683 0.67
SCHEMBL2884436 0.67
SCHEMBL44197 0.67
SCHEMBL27883313 0.67
SCHEMBL27798770 0.63
Ethyne SCHEMBL7610107 0.63
SCHEMBL28285000 0.63
Methane SCHEMBL22749558 0.63
Butadiene SCHEMBL10934316 0.60

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4377311-A1 2-DIAZO-3-OXO-2,3-DIHYDROSPIRO[INDENE-1,9'-XANTHENE] DERIVATIVES AND SIMILAR COMPOUNDS AS PHOTOACTIVE FLUORESCENT COMPOUNDS FOR PROTEIN LABELING Eikon Therapeutics Inc. (US) 2024-06-05 EP disclosed
US-11981703-B2 Polynucleotide constructs SIRIUS THERAPEUTICS, INC. (US) 2024-05-14 US disclosed
CN-117642185-A Improved CD30 targeting antibody drug conjugates and uses thereof 路德维希-马克西米利安慕尼黑大学 2024-03-01 CN disclosed
US-20230348453-A1 HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF IOMX THERAPEUTICS AG (DE) 2023-11-02 US disclosed
EP-4267193-A1 IMPROVED CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF Ludwig-Maximilians-Universität München (DE) 2023-11-01 EP disclosed
US-20230321083-A1 Inhibitors of GPR174 and Uses Thereof OMEROS CORP (US) 2023-10-12 US disclosed
US-20230285556-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER OMEROS CORPORATION 2023-09-14 US disclosed
US-20230242567-A1 CHIRAL PHOSPHORAMIDITE AUXILIARIES AND METHODS OF THEIR USE SIRIUS THERAPEUTICS, INC. 2023-08-03 US disclosed
CN-111315744-B Heteroaryl tetrahydropyridine compound, preparation method, pharmaceutical composition and application thereof 四川科伦博泰生物医药股份有限公司 2023-07-14 CN disclosed
US-20230192701-A1 BICYCLIC KINASE INHIBITORS AND USES THEREOF IOMX THERAPEUTICS AG (DE) 2023-06-22 US disclosed
US-20060116368-A1 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor JANSSEN PHARMACEUTICA N.V. (BE) 2006-06-01 US disclosed
US-6984647-B2 Aminotetralin-derived urea modulators of vanilloid VR1 receptor JANSSEN PHARMACEUTICA N.V. (BE) 2006-01-10 US disclosed
US-20050288281-A1 Hetero isonipecotic modulators of vanilloid VR1 receptor JANSSEN PHARMACEUTICA NV (BE) 2005-12-29 US disclosed
US-20050187291-A1 use of 2-(urea or thiourea)tetralins as analgesic or to treat pulmonary dysfunction JANSSEN PHARMACEUTICA, N.V. (BE) 2005-08-25 US disclosed
US-20050171099-A1 3-(diheteroarylmethylene)-8-azabicyclo[3.2.1]octane and 3-((aryl)(heteroaryl)methylene)-8-azabicyclo[3.2.1]octane derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2005-08-04 US disclosed
US-20040192728-A1 Quinoline-derived amide modulators of vanilloid VR1 receptor JANSSEN PHARMACEUTICA N.V. (BE) 2004-09-30 US disclosed
US-6794530-B1 1,4-ADDITION OF MONOHYDRIC OR POLYHYDRIC ALCOHOLS TO ALPHA , BETA -UNSATURATED NITRILES BASF AKTIENGESELLSCHAFT (DE) 2004-09-21 US disclosed
US-20040157865-A1 Naphthol, quinoline and isoquinoline-derived urea modulators of vanilloid VR1 receptor JANSSEN PHARMACEUTICA, N.V. (BE) 2004-08-12 US disclosed
US-20030236280-A1 Aminotetralin-derived urea modulators of vanilloid VR1 receptor JANSSEN PHARMACEUTICA, N.V. (BE) 2003-12-25 US disclosed
US-6348596-B1 NUCLEIC ACID HYBRIDIZATION ASSAYS; DNA SEQUENCE DETERMINATION PE CORPORATION (NY) 2002-02-19 US disclosed